BR0313515A - Terapia de gene para isquemia de membro crìtica com enos do tipo selvagem ou mutante - Google Patents
Terapia de gene para isquemia de membro crìtica com enos do tipo selvagem ou mutanteInfo
- Publication number
- BR0313515A BR0313515A BR0313515-2A BR0313515A BR0313515A BR 0313515 A BR0313515 A BR 0313515A BR 0313515 A BR0313515 A BR 0313515A BR 0313515 A BR0313515 A BR 0313515A
- Authority
- BR
- Brazil
- Prior art keywords
- enos
- mutant
- gene therapy
- wild type
- polypeptides
- Prior art date
Links
- 238000001415 gene therapy Methods 0.000 title abstract 2
- 201000002818 limb ischemia Diseases 0.000 title 1
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 abstract 5
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 abstract 5
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 abstract 2
- 206010034576 Peripheral ischaemia Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 208000028867 ischemia Diseases 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13
- C12N9/0075—Nitric-oxide synthase (1.14.13.39)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40363702P | 2002-08-16 | 2002-08-16 | |
| PCT/US2003/025626 WO2004016761A2 (en) | 2002-08-16 | 2003-08-15 | Gene therapy for critical limb ischemia with wild type or mutant enos |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0313515A true BR0313515A (pt) | 2005-10-18 |
Family
ID=31888259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0313515-2A BR0313515A (pt) | 2002-08-16 | 2003-08-15 | Terapia de gene para isquemia de membro crìtica com enos do tipo selvagem ou mutante |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20040120930A1 (enExample) |
| EP (1) | EP1536689A4 (enExample) |
| JP (1) | JP2005539031A (enExample) |
| KR (1) | KR20050042162A (enExample) |
| CN (2) | CN101391105A (enExample) |
| AU (1) | AU2003263844A1 (enExample) |
| BR (1) | BR0313515A (enExample) |
| CA (1) | CA2494845A1 (enExample) |
| IL (1) | IL166362A0 (enExample) |
| MX (1) | MXPA05001763A (enExample) |
| NO (1) | NO20051351L (enExample) |
| PL (1) | PL375446A1 (enExample) |
| RU (1) | RU2005107414A (enExample) |
| WO (1) | WO2004016761A2 (enExample) |
| ZA (1) | ZA200502181B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014123749A1 (en) * | 2013-01-30 | 2014-08-14 | Board Of Regents Of The University Of Nebraska | Compositions and methods for treating complications associated with diabetes |
| US20190284263A1 (en) * | 2016-04-29 | 2019-09-19 | Inovio Pharmaceuticals, Inc. | In vivo use of chondroitinase and/or hyaluronidase to enhance delivery of an agent |
| CN105944243A (zh) * | 2016-05-12 | 2016-09-21 | 段俊丽 | 一种eNOS表达与活化的调控装置及周围动脉疾病的治疗装置 |
| KR20200013674A (ko) * | 2017-05-02 | 2020-02-07 | 유니버시티 오브 마이애미 | 허혈 조직을 치료하는 방법 |
| CN107802826B (zh) * | 2017-10-26 | 2020-02-18 | 首都医科大学宣武医院 | eNOS突变体在促进血管生成中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1061800A4 (en) * | 1998-03-09 | 2004-10-06 | Caritas St Elizabeths Boston | COMPOSITIONS AND METHODS FOR MODULATING THE VASCULARIZATION |
| EP1016726A1 (en) * | 1998-12-30 | 2000-07-05 | Introgene B.V. | Gene therapy to promote angiogenesis |
| WO2000062605A1 (en) * | 1999-04-16 | 2000-10-26 | Yale University | eNOS MUTATIONS USEFUL FOR GENE THERAPY AND THERAPEUTIC SCREENING |
-
2003
- 2003-08-15 JP JP2004529471A patent/JP2005539031A/ja active Pending
- 2003-08-15 BR BR0313515-2A patent/BR0313515A/pt not_active IP Right Cessation
- 2003-08-15 EP EP03788540A patent/EP1536689A4/en not_active Withdrawn
- 2003-08-15 CA CA002494845A patent/CA2494845A1/en not_active Abandoned
- 2003-08-15 WO PCT/US2003/025626 patent/WO2004016761A2/en not_active Ceased
- 2003-08-15 CN CNA2008101259592A patent/CN101391105A/zh active Pending
- 2003-08-15 PL PL03375446A patent/PL375446A1/xx not_active Application Discontinuation
- 2003-08-15 US US10/642,255 patent/US20040120930A1/en not_active Abandoned
- 2003-08-15 KR KR1020057002657A patent/KR20050042162A/ko not_active Ceased
- 2003-08-15 AU AU2003263844A patent/AU2003263844A1/en not_active Abandoned
- 2003-08-15 MX MXPA05001763A patent/MXPA05001763A/es not_active Application Discontinuation
- 2003-08-15 CN CNB038194945A patent/CN100408101C/zh not_active Expired - Fee Related
- 2003-08-15 RU RU2005107414/13A patent/RU2005107414A/ru not_active Application Discontinuation
-
2005
- 2005-01-18 IL IL16636205A patent/IL166362A0/xx unknown
- 2005-03-15 NO NO20051351A patent/NO20051351L/no not_active Application Discontinuation
- 2005-03-15 ZA ZA200502181A patent/ZA200502181B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1536689A4 (en) | 2006-09-06 |
| IL166362A0 (en) | 2006-01-16 |
| MXPA05001763A (es) | 2005-08-19 |
| JP2005539031A (ja) | 2005-12-22 |
| AU2003263844A1 (en) | 2004-03-03 |
| US20040120930A1 (en) | 2004-06-24 |
| EP1536689A2 (en) | 2005-06-08 |
| CA2494845A1 (en) | 2004-02-26 |
| NO20051351L (no) | 2005-04-28 |
| WO2004016761A3 (en) | 2005-03-17 |
| CN100408101C (zh) | 2008-08-06 |
| PL375446A1 (en) | 2005-11-28 |
| CN101391105A (zh) | 2009-03-25 |
| CN1688197A (zh) | 2005-10-26 |
| WO2004016761A2 (en) | 2004-02-26 |
| RU2005107414A (ru) | 2006-01-27 |
| KR20050042162A (ko) | 2005-05-04 |
| ZA200502181B (en) | 2006-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0211915A (pt) | Execução de aplicação habilitada para teste | |
| BR9915940A (pt) | Métodos e composições para restaurar a estabilidade conformacional de uma proteìna da famìlia p53 | |
| BR0011342A (pt) | Métodos para a modulação de diabetes tipo 2, para modular a resistência à insulina, para alìvio de hiperlipidemia e para tratamento de hiperuricemia em um mamìfero, e, composição farmacêutica | |
| BRPI0409678A (pt) | métodos para identificar um composto, para tratar ou prevenir uma doença ou distúrbio em um humano, para incrementar a função de órgãos, tecidos, ou células excitáveis em um humano e para modular a atividade de um complexo de receptores de citocinas protetor de tecidos em um humano | |
| BR0316923A (pt) | Polipeptìdeo mitoneet de membranas mitocondriais, seus moduladores e métodos para utilização do mesmo | |
| ES2153831T3 (es) | Inhibidores de dipeptidil-aminopeptidasa de tipo iv. | |
| PT1017384E (pt) | Compostos com base no azabenzimidazole para modulacao da funcao de uma cinase de proteina serina/treonina | |
| BR0317872A (pt) | Medicamentos antiinflamatórios | |
| ES2159184T3 (es) | Nueva posologia para la dmni. | |
| DE69233478T8 (de) | Neue menschliche cdc25 gene, kodierte produkte und ihre verwendung | |
| ID26956A (id) | Pencegahan raf kinase menggunakan simetris dan nonsimetris yang digantikan diphenil urea | |
| DE69434385D1 (de) | Cck-2, eine rezeptor tyrosin kinase | |
| BRPI0415510A (pt) | terapia fotodinámica para redução local de adipócito | |
| BRPI0510663A (pt) | pelo menos uma entidade quìmica, composição, métodos para modular atividade da cinesina cenp-e, para inibir cenp-e, e para tratar uma doença proliferativa celular, e, uso de pelo menos uma entidade quìmica | |
| BRPI0411020A (pt) | perfil de expressão de gene, métodos de identificar agentes modulares do caminho de wnt, de preparar um perfil de expressão de gene, de triar um agente que realce a remodelagem associada com a carga óssea e reagentes que se ligam às proteìnas que modulam a remodelagem óssea e/ou mineralização óssea, de tratar uma doença ou distúrbio de mineralização óssea, de modular a mineralização óssea em uma célula e a mineralização óssea e/ou remodelagem óssea em um paciente e de determinar se um composto ou uma composição realçam o efeito de carga óssea na atividade/função e/ou mineralização da célula óssea, agente candidato para tratar uma condição de massa óssea baixa e composição | |
| BR9507467A (pt) | Processos para produzir um inibidor de serina-protease recombinante modular uma serina-protease diagnosticar pacientes suspeitos de apresentarem uma mutação em um gene codificador de um inibidor de serina-protease tratar uma condição associada ás serina-proteases em um paciente e inibir os mecanismos moleculares e celulares da inflamação e reduzir os danos nos tecidos em uma célula ou tecido composição capaz de modular efetivamente a atividade de serina-protease uso da composição análogo de a-1- antiquimotripsina do tipo selvagen humana sequência de ácidos nucléicos vetor de expressão célula hospedeira e preparação de protina | |
| BR0313515A (pt) | Terapia de gene para isquemia de membro crìtica com enos do tipo selvagem ou mutante | |
| ATE341639T1 (de) | Adenovirus-vermittelte gentherapie | |
| BR0108728A (pt) | Combinação farmacêutica terapêutica, e, método para tratar um c ncer. | |
| BR0012676A (pt) | Métodos para tratamento de tumores resistentes a terapia | |
| NO20051347L (no) | eNOS-mutanter som er nyttige til genterapi. | |
| BR0114407A (pt) | Mutantes de quimiocina no tratamento de esclerose múltipla | |
| BR0311448A (pt) | Métodos para sensibilizar uma célula neoplástica a radiação, para tratar ou melhorar um tumor em um paciente, e para impedir um tumor de desenvolver resistência à radiação em um paciente | |
| BR9908443A (pt) | Linhagens de células de medula espinhal humana e métodos para uso das mesmas | |
| BR9812875A (pt) | Processos para o tratamento de artrite reumatóide em um mamìfero, e para a fabricação de uma composição terapêutica para o tratamento de artrite reumatóide em um mamìfero, uso de um composto, e, composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2069 DE 31/08/2010. |